PALI (Palisade Bio) Other Financing: $134.89 Mil (TTM As of Mar. 2026)


PALI Palisade Bio Inc PALI
35 GF Score
Price $2.23
! 2 Warning Signs
View Full Analysis

What is Palisade Bio Other Financing?

Palisade Bio PALI +18.21% 35 Other Financing is $134.89 Mil as of Mar. 2026. GuruFocus rates PALI with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Palisade Bio's Other Financing for the three months ended in Mar. 2026 was $-0.05 Mil.

Palisade Bio's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $134.89 Mil.

Palisade Bio Other Financing Historical Data

* Premium members only.

The historical data trend for Palisade Bio's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio Other Financing Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -0.32 1.65 2.16 1.57 6.54

Palisade Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 0.00 3.46 131.47 -0.05
PALI
35GF Score
Palisade Bio Inc PALI
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palisade Bio Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $134.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $134.89 Mil mean?
Palisade Bio (PALI) has a Other Financing of $134.89 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Palisade Bio and its competitors.
Is Palisade Bio's Other Financing too high?
Palisade Bio's current Other Financing is $134.89 Mil. Overall, Palisade Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's Other Financing compare to IRD and GALT?
Palisade Bio's Other Financing of $134.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Palisade Bio and its competitors. Palisade Bio's current Other Financing is $134.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (PALI) has a current Other Financing of $134.89 Mil. The current Other Financing is $134.89 Mil. Palisade Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Palisade Bio (PALI), the current Other Financing is $134.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palisade Bio Business Description

Address 4600 South Syracuse Street, Suite 900, Denver, CO, USA, 80237
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
35GF Score

Get the complete analysis for PALI

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.23
Price